Introducing CLIMB Clinical 2024

CLIMB Clinical 2024 offers four full-length topics to increase your knowledge and skills in complex clinical areas: Atrial Fibrillation, Heart Failure, Prevention and Structural Imaging. This year, we are also offering a 3-month pilot program in ATTR-CM for skill development in this fast-growing field. 

CLIMB seeks to provide women physicians with access to advanced procedural training in a supportive, small-group format. By offering this opportunity for participants to grow and develop their skill sets, we aim to identify the next generation of women leaders in cardiology.

CLIMB Clinical is open to applications from women physicians who have completed fellowship (specialist) training. Women cardiologists who are currently in training are also welcome to apply, with Program Director approval.

  • Online learning
  • Multiple learning paths
  • Open to worldwide applicants
  • 100% free

Program Timeline

The key dates you need to know.

April 12
Application window opens
May 22
Application window closes
June 3
Successful applicants notified
July – Dec.
Program period
*ATTR-CM Oct-Dec

2024 CLIMB Clinical Topics

Each topic will consist of monthly 90-minute webinar sessions. Sessions will include a mix of didactic presentations, case reviews, and group discussions. Learn more about each of this year’s topics, including the world-leading Program Directors who will guide your learning.

ATRIAL FIBRILLATION

Co-sponsored by

What will you learn?

  • Fundamentals of Atrial Fibrillation
  • AF Ablation & Procedures
  • Special Circumstances in AF
  • Stroke Risk Reduction
  • Complication Management
  • AF Clinical Trials

Program Directors

  • Emily Zeitler, MD, MHS
    Emily Zeitler, MD, MHS
    Dartmouth Hitchcock Medical Center, Lebanon, NH, USA
  • Andrea Sarkozy, MD, PhD
    Andrea Sarkozy, MD, PhD
    University Hospital of Brussels, Belgium

HEART FAILURE

What will you learn?

  • HFpEF Diagnosis and Management
  • Hypertrophic Cardiomyopathy
  • Cardio-Oncology
  • Comorbidities
  • Devices and Structural Interventions
  • Advanced Heart Failure
  • Clinical trials

Program Directors

  • Bonnie Ky, MD, MSCE
    Bonnie Ky, MD, MSCE
    University of Pennsylvania, Philadelphia, PA, USA
  • Clara Saldarriaga, MD
    Clara Saldarriaga, MD
    University of Antioquia, Medellín, Colombia

PREVENTION

What will you learn?

  • CV Risk Stratification
  • Tackling Obesity
  • Diabetes
  • Lipid Management – LDL & Triglycerides and Lp(a)
  • Management of CV risk in women

Program Directors

  • Pam Taub, MD
    Pam Taub, MD
    UC San Diego Health System, San Diego, CA
  • Malissa Wood, MD
    Malissa Wood, MD
    Lee Health Heart Institute, Fort Myers, FL

STRUCTURAL IMAGING

What will you learn?

  • Basics of Structural Imaging
  • Intraprocedural Guidance for TAVI
  • Candidate Selection for Mitral Procedures
  • Guiding Annuloplasty
  • Paravalvular Leaks and LAA Occlusion

Program Directors

  • Julia Grapsa, MD
    Julia Grapsa, MD
    Royal Brompton and Harefield NHS Trust, London, UK
  • Marta Sitges, MD, PhD
    Marta Sitges, MD, PhD
    Hospital Clinic, University of Barcelona, Spain

*New Pilot Topic*

ATTR-CM

What will you learn?

  • 3 types of amyloid cardiomyopathy – presentation and diagnosis
  • Understanding the patient journey
  • Imaging modalities to facilitate diagnosis
  • The role of AI in diagnosis of ATTR-CM
  • Factors contributing to underdiagnosis in women
  • Current clinical trials and advances in treatment

Program Directors

  • Grace Lin, MD, MBA
    Grace Lin, MD, MBA
    Mayo Clinic, Rochester, MN, USA
  • Professor Thibaud Damy, MD, PhD
    Professor Thibaud Damy, MD, PhD
    University Hospital Henri Mondor, Creteil, France

Sponsored by

Frequently asked questions

CLIMB Clinical topics are open to women cardiologists who have completed fellowship (specialist) training. Women cardiologists who are currently in training can apply to participate with Program Director approval. You will need;

  • A complete Women as One Talent Directory profile.
  • A letter of interest indicating your reason for applying, your current institutional resources and procedural experience, and your commitment to the programmatic components.
  • A letter of support from your Lab Director or another Institutional Leader.

 

Participants are asked to be present for six 90-minute webinars, which will take place once per month between July and December 2024. The ATTR-CM pilot program will consist of three 90-minute webinars between October-December. Homework, which includes preparing case presentations, will also be required for most topics.

We ask that applicants apply for one full-length topic only. At the point of application you can also choose to opt-in to the ATTR-CM Pilot Program.

CLIMB is not accredited for CME.

The CLIMB program is completely free!

CLIMB 2024 applications opened on April 12 and close on May 22.

Yes. We welcome previous CLIMB participants to this year’s program.

What past participants say about CLIMB

Since 2020, CLIMB has supported women physicians in gaining new clinical skills. Discover the impact on some of the program alumnae.

Our CLIMB sponsors

Thank you to the generous sponsors that are supporting CLIMB Clinical 2024.

Emily Zeitler, MD, MHS
Dartmouth Hitchcock Medical Center, Lebanon, NH, USA

Emily Zeitler is an Assistant Professor of Medicine at the Geisel School of Medicine and The Dartmouth Institute as well as clinical faculty at the Dartmouth-Hitchcock Medical Center in clinical cardiac electrophysiology. Dr. Zeitler graduated from Emory Medical School in 2008 with honors and received her clinical training in internal medicine at Massachusetts General Hospital. She completed clinical fellowships in cardiology and electrophysiology at Duke University. While at Duke University, Dr. Zeitler completed two years of training in clinical research as a T32 fellow at the Duke Clinical Research Institute and earned a Masters in Health Sciences. Dr. Zeitler has experience in medical device regulatory policy having worked previously at the US Food and Drug Administration as a medical device officer, and she remains interested and engaged in device regulatory policy and general heart rhythm-related health policy. Dr. Zeitler is deeply involved in cardiovascular outcomes research broadly with a particular interest in outcome disparities related to implantable medical devices and atrial fibrillation.

Andrea Sarkozy, MD, PhD
University Hospital of Brussels, Belgium

Prof. Andrea Sarkozy graduated in 1995 from the Semmelweis Medical University of Budapest, Hungary. Following her internal medicine and cardiology training, she completed a clinical electrophysiology fellowship training at the St. Michael’s Hospital of the University of Toronto in Canada for further specialization in the field of interventional electrophysiology. Between 2007 and 2013 she was Director of the Clinical Electrophysiology Program of the Heart Rhythm Management Center in the University Hospital of Brussels, Belgium, where she completed her PhD entitled “Brugada syndrome: facts and controversies”, under the guidance of Prof. Pedro Brugada. Between 2013 and 2022 she was director of the Electrophysiology Program of the Cardiology department of the University Hospital of Antwerp and professor at the University of Antwerp. Since February 2023, she is the director of the Ventricular Arrhythmia and Sudden Death Prevention Unit of the Heart Rhythm Management Center of the University Hospital of Brussels and professor at the Free University of Brussels.

Prof. Sarkozy is since 2017 Fellow of the European Heart Rhythm Association, between 2014 and 2017 she was board member of the EHRA, between 2017 and 2020 she was EHRA webinar course director and since 2022 she is scientific program co-chair of the EHRA congress. She is an internationally recognized expert in the field of cardiac electrophysiology. She is author of >150 scientific publications in international peer-reviewed journals and co-author of several international guidelines in the field of Brugada syndrome and catheter ablation of complex cardiac arrhythmias. She serves as principal investigator and national clinical trial coordinator in multiple international multicenter trials and as reviewer in several international cardiology and electrophysiology journals.

Bonnie Ky, MD, MSCE
University of Pennsylvania, Philadelphia, PA, USA

Dr. Bonnie Ky is the Founder’s Professor of Cardio-Oncology and physician scientist at the University of Pennsylvania. She leads a highly active NIH- and AHA-funded clinical translational research program in cardio-oncology with the fundamental goals of advancing actionable science to improve the cardiovascular care of our cancer patients. She is the Principal Investigator of multiple cohort studies focused on determining individual patient risk, through detailed phenotyping of the social determinants of health, clinical, biologic markers, and imaging-derived measures of cardiac function, and clinical trials focused on mitigating cardiovascular risk. She is the Director of the Thalheimer Center for Cardio-Oncology, the Founding Director of the Penn Translational Cardio-Oncology Center of Excellence, and Director of the Penn Center for Quantitative Echocardiography. She is an invited member of many cardio-oncology expert consensus groups focused on advancing our understanding of cardiovascular disease in the growing cancer population within the NIH, FDA, American Society of Clinical Oncology, American College of Cardiology, American Heart Association, and European Society of Cardiology. She is a standing member and Chair of the NIH Clinical Integrative Cardiovascular and Hematological Sciences Study Section and inaugural Chair of the ECOG-ACRIN Cardiotoxicity subcommittee. She is the Inaugural, founding Editor-in-Chief of JACC: CardioOncology, inducted member of the American Society of Clinical Investigation and the Association of American Physicians, member of the Sarnoff Research Committee, elected member of the American College of Cardiology Board of Trustees; and recipient of the International Cardio-Oncology Society Thomas Force Leadership Award and ECOG-ACRIN Young Investigator Award.

Clara Saldarriaga, MD
University of Antioquia, Medellín, Colombia

Professor Clara Saldarriaga FACC – FESC is the head of the cardiology program for Pontificia Bolivariana and the leader of the heart failure program for CardioVID clinic in University in Medellín – Colombia . She is the elected president for the Colombian Society of cardiology, The governor for Colombia´s ACC chapter and member of the Lancet Commission for cardiovascular disease in women. She is also principal investigator and steering committee for heart failure trials. 

Pam Taub, MD
UC San Diego Health System, San Diego, CA

Pam R. Taub, MD, FACC, FASPC is a board-certified cardiologist and internationally recognized expert in cardiometabolic disease.

She is the founding director of the Step Family Foundation Cardiac Rehabilitation and Wellness Center and Professor of Medicine at UC San Diego. Dr. Taub was responsible for all aspects of creating the center, which provides a comprehensive cardiac rehabilitation program for patients with established heart disease.   
 
Her clinical practice focuses on preventive cardiology, lipidology, as well as women’s cardiovascular health. Her research focuses on assessing the impact of behavioral, technological, and pharmacological interventions on cardiometabolic disease. Dr. Taub’s is a federally funded researcher with funding from: the National Institutes of Health (Principal Investigator on R01 grant), Department of Defense, Department of Homeland Security and American Heart Association. She is an experienced clinical trialist and serves on the executive committee for multiple international clinical trials focused on novel cardiovascular therapies.

Dr. Taub is widely published (with over 100 publications) and has authored high impact publications in top peer-reviewed journals including Cell Metabolism and the Journal of the American College of Cardiology that have impacted clinical practice.

Dr. Taub holds multiple leadership positions in professional societies, serving as a fellow and board member for the American Society of Preventive Cardiology. She is a fellow and member of the American College of Cardiology Prevention of CV Disease Section Leadership Council. She also serves as the Vice-Chair of the American Heart Association Council Women in Cardiology Committee.

Malissa Wood, MD
Lee Health Heart Institute, Fort Myers, FL

Dr. Wood completed her undergraduate and medical degrees in the combined B.A/M.D   program from the University of Missouri-Kansas City followed by training in internal medicine and cardiovascular medicine at  the Beth Israel Deaconess Medical Center/Harvard Medical School in Boston, Massachusetts where she served as Chief Medical Resident.  Dr. Wood joined the staff of Massachusetts General Hospital in 2000 where she held the Cathy E. Minehan Chair of Cardiovascular Disease in Women and co-directed the Corrigan Women’s Heart Health Program and the MGH Multidisciplinary SCAD Program. Dr. Wood served as the Associate Chief of Cardiology for Diversity and Health Equity.  Dr. Wood is a dedicated advocate for her patients and colleagues and has been involved in successful advocacy efforts at the state and national levels. She has led publications which have addressed the impact of social determinants of health on cardiovascular care, identified existing disparities in care has worked tirelessly to advance diversity in the field of cardiovascular medicine. Dr. Wood is on the Steering Committee of the iSCAD Registry and is the immediate-past Chair of the ACC Board of Governors and former Trustee of the ACC.  In July 2023, she was appointed Vice President and Chief Physician Executive of the Lee Health Heart Institute in Fort Myers, Florida.

Julia Grapsa, MD
Royal Brompton and Harefield NHS Trust, London, UK

Julia Grapsa has been a consultant cardiologist at Guy’s and St Thomas’ NHS Foundation Trust since March 2020. She leads the imaging team for tricuspid services. She is also a Reader for King’s College London. She was the founding editor in chief, for JACC Case Reports, under American College of Cardiology. She owns the foundation of JACC Case Reports Peer Review Mentoring Program and other initiatives such as DaVinci corner. She is now delighted to work under ESC journals as a senior editor for EHJ-IMP. She chairs the women in imaging task force under the European Association of Cardiovascular Imaging (EACVI), European Society of Cardiology (ESC). She was also a secretary (treasurer) for the ESC valvular heart disease council and prior to that, lead for the ESC clinical case gallery under ESC education. She is a fellow for the Royal College of Physicians (RCP), European Society of Cardiology (ESC), European Association of Cardiovascular Imaging (EACVI) American Society of Echocardiography (ASE), American College of Cardiology (ACC). Her first consultant job was in Royal Papworth Hospital and Queen Elizabeth King’s Lynn NHS Foundation Trusts. She was the lead for the echocardiography department at Kingston Hospital. She was one of the first women to work for Cleveland Clinic Abu Dhabi. From September 2018 she was the lead for the echocardiography department for Royal London Hospital and a consultant cardiologist for Bart’s Health NHS Trust. She was the first author of the British guidelines for echocardiography in pulmonary hypertension. She has participated in European and American position papers and guidelines. She has authored more than 140 peer reviewed publications and 5 book chapters. She participated in the CLIMB program under Women as One in 2021.

Marta Sitges, MD, PhD
Hospital Clinic, University of Barcelona, Spain

Marta Sitges is a non-invasive imaging cardiologist who completed her Degree in Medicine and Surgery in the Universitat Autònoma de Barcelona in 1993. Since that time she has worked at the Hospital Clínic (Barcelona, Spain) as resident, research fellow and then as a permanent staff cardiologist. She also visited the Cardiovascular Imaging Center at the Cleveland Clinic Foundation, USA, during a 1-year cardiac imaging fellowship. In 2003, she obtained her PhD degree from the Universitat de Barcelona, Spain, focusing on the effects of hormonal replacement therapy on vascular reactivity. Her main research interests currently consist in cardiac imaging, valvular heart disease and cardiac remodeling in heart failure and sport practice. She has published more than 400 peer reviewed papers (H index 70, i10 269), presented more than 400 lectures in National and International meetings, written 36 book chapters, received 60 grants, including H2020 projects and prizes and supervised 14 PhD thesis. She is also referee for most of the principal cardiovascular journals and a referral for echocardiography in a broad spectrum of clinical fields but mainly related to heart valve disease. She was certified in “Management of Integrated Health Systems” by the business school ESADE in 2012. She is the coordinator of the Sports Cardiology Group at Hospital Clinic and responsible of the program of Sports Cardiology at FC Barcelona since 2009. She has been staff cardiologist since 2001 at the Cardiovascular Institute in Hospital Clinic in Barcelona, Head of Cardiac Imaging from 2013 to 2015 and currently, Director of the Cardiovascular Institute since October 2015. She has been member of the Board of Directors since 2017, President and currently Past-President of the Heart Valve Society. She was appointed as Associate Professor in 2010 and Full Professor of Medicine at the University of Barcelona in 2020.
Orcid: orcid.org/0000-0003-1300-4732

Grace Lin, MD, MBA
Mayo Clinic, Rochester, MN, USA

Grace Lin is a Professor of Medicine, advanced heart failure cardiologist and echocardiographer at Mayo Clinic. In her role as Vice Chair of the Division of Circulatory Failure at Mayo Clinic she oversees clinical operations and enterprise practice standardization for heart failure. Her clinical expertise and academic interests are focused on cardiac amyloidosis and cardio-oncology. She is committed to improving healthcare access for individuals with cardiovascular disease through practice innovations in healthcare delivery including digital health and remote monitoring as well as new models of community and home-based care. Dr. Lin is currently serving as a Robert Wood Johnson Foundation Health Policy Fellow as a Visiting Scholar in the Congressional Budget Office.

Dr. Lin is a nationally recognized expert in cardiac amyloidosis and has served as a principal investigator in clinical trials for amyloid heart disease. She is the heart failure lead for the Mayo Echo Core Laboratory which directs imaging for multi-center heart failure clinical trials. Dr. Lin spearheaded a practice innovation to deliver in-home intermediate acuity care for acute decompensated heart failure as an alternative to hospitalization in partnership with the community para medicine group. She has advised several startup companies developing digital health tools for heart failure management and directs the heart failure remote monitoring program at Mayo Clinic. She is a fellow of the American College of Cardiology and the American Society of Echocardiography.

Dr. Lin received her undergraduate degree with honors and special honors from the University of Chicago and an MD from the Loyola University Chicago Stritch School of Medicine. She completed internal medicine residency and cardiology training at Mayo Clinic, and is board certified in echocardiography, cardiovascular diseases, and advanced heart failure and transplant. In 2021, she received an MBA from the University of Chicago Booth School of Business, where her team was winner of the 2021 Global New Ventures Competition for their digital health innovation to remotely screen for valvular heart disease.

Professor Thibaud Damy, MD, PhD
University Hospital Henri Mondor, Creteil, France

Pr Thibaud Damy’s field of interest are Heart failure and Cardiac Amyloidosis, through to their diagnosis and treatment. His particular current interests are developpement of HF Nurses in France and improving CA diagnosing and treatment at the national level. He is working at the Hospital Henri Mondor, at Paris East Creteil University (UPEC) and at INSERM U955 (Clinical EPidemiology in Aging (CEPIA). He is leading the Referral Center for Cardiac Amyloidosis from the Cardiogen French Network /ERN. He and his team created a wide educational programme to improve the knowledge and quality of life of the patients (Amylo-PEP). He is leading the French National Amyloidosis Network gathering and the Healthcare European Amyloidosis Registry that has included around 4500 patients with amyloidoisis. He is a co-author of around 240 articles (~100 on amyloidosis). He is coordinating several websites : www.reseau-amylose.org, www.vaincrelinsuffisancecardiaque.org